Rexmyelocel TAlternative Names: BM-MNCs - Rexgenero; REX-001
Latest Information Update: 08 Aug 2016
At a glance
- Originator Rexgenero
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Peripheral ischaemia
Most Recent Events
- 07 Jul 2016 Phase-III clinical trials in Peripheral ischaemia in Spain (Intra-arterial) (EudraCT2016-000240-34)
- 14 Apr 2016 The UK Medicines and Healthcare Products Regulatory Agency (MHRA) grants Promising Innovative Medicine Designation (PIM) for Rexmyelocel-T for the treatment of Peripheralischemia